Previous 10 | Next 10 |
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences: Stifel 2022 Healthcare Conference . Zymeworks’ manageme...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
Institutional Shareholder Services joins Glass Lewis in recommending a vote FOR the Redomicile resolution ISS cites potential for improved capital raising ability and commercialization efficiencies for the Company's lead product candidate, zanidatamab To vote, contac...
Independent proxy advisory firm Glass Lewis recommends that Zymeworks shareholders vote FOR the Redomicile resolution Glass Lewis notes Zymeworks has made a compelling case that the Redomicile will favor the Company on the basis of more favorable corporate law To...
Company to hold conference call and webcast on Monday, September 12 th at 4:30 PM Eastern Standard Time (EST) Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented preliminary results from ...
Redomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better position the Company for future growth Zymeworks Board recommends that Zymeworks securityholders vote FOR the Redomicil...
The shares of oncology-focused biotech Zymeworks Inc. ( NYSE: ZYME ) dropped ~19% Tuesday as Wall Street reacted to the company’s announcement on Phase 1 data for its antibody-drug conjugate zanidatamab zovodotin (ZW49) in patients with solid tumors. The data released...
Zanidatamab zovodotin shown to have manageable safety profile with encouraging, single-agent anti-tumor activity in patients with HER2+ cancers Results to be reviewed in an oral presentation at European Society for Medical Oncology (ESMO) Congress 2022 in Paris Monday, Septe...
Zymeworks Inc. (ZYME) Q2 2022 Results Conference Call August 04, 2022 04:30 PM ET Company Participants Jack Spinks - Associate Director of Investor Relations Ken Galbraith - Chair and CEO Dr. Neil Josephson - CMO Conference Call Participants Yigal Noc...
Zymeworks press release ( NYSE: ZYME ): Q2 Non-GAAP EPS of -$0.92 beats by $0.02 . Revenue of $5.44M (+207.3% Y/Y) misses by $0.02M . For further details see: Zymeworks Non-GAAP EPS of -$0.92 beats by $0.02, revenue of $5.44M misses by $0.02M
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...